Actuate Therapeutics Inc (ACTU) annual cash flow statement — 4-year operating, investing & financing history
| Cash from Operations | -19.78M | -19.21M | -21.84M | -21.63M | -17.79M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | -22.56% | 12.07% | -1.01% | -21.53% | - |
| Net Income | -21.54M | -22.23M | -27.29M | -24.74M | -20.16M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.7M | 6.05M | 2M | 423.54K | 654.07K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.56M | 20.25K | 2.35M | 123.46K | -20.38K |
| Working Capital Changes | -4.5M | -3.05M | 1.1M | 2.57M | 1.73M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.46M | -512.54K | -1.5M | 1.29M | 586.26K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 24.02M | 23.72M | 27.53M | 4.13M | 19.26M |
| Debt Issued (Net) | 0 | 0 | 5.5M | 0 | 0 |
| Equity Issued (Net) | 24.68M | 24.03M | 23.96M | 4.13M | 19.26M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -655.32K | -302.82K | -1.93M | 0 | 0 |
| Net Change in Cash | 4.24M | 4.52M | 5.68M | -17.49M | 1.46M |
| Free Cash Flow | -19.78M | -19.21M | -21.84M | -21.63M | -17.79M |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | 6.76% | 12.07% | -1.01% | -21.53% | - |
| FCF per Share | -0.84 | -0.91 | -1.12 | -1.44 | -1.18 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.86x | 0.80x | 0.87x | 0.88x |
| Interest Paid | 70.96K | 0 | 71.03K | 0 | 0 |
| Taxes Paid | 0 | 0 | 800 | 0 | 0 |
Quick answers to the most common questions about buying ACTU stock.
Actuate Therapeutics Inc (ACTU) generated $-19.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Actuate Therapeutics Inc (ACTU) reported negative free cash flow of $19.2M in 2025, indicating capital requirements exceeded cash from operations.
Actuate Therapeutics Inc (ACTU) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.